The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).
Articolo
Data di Pubblicazione:
2004
Abstract:
Based on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy. Eleven (35%) patients tolerated the 400 mg/d thalidomide dose. Overall, 15 (48%) patients achieved hematologic response, with 6 (19%) complete remissions and 8 (26%) organ responses. Median time to response was 3.6 months (range, 2.5-8.0 months). Treatment-related toxicity was frequent (65%), and symptomatic bradycardia was a common (26%) adverse reaction. The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
THALIDOMIDE; DEXAMETHASONE; AMYLOIDOSIS
Elenco autori:
Palladini, Giovanni; Perfetti, V.; Perlini, Stefano; Obici, L.; Lavatelli, Francesca; Caccialanza, R.; Invernizzi, Rosangela; Comotti, B.; Merlini, Giampaolo
Link alla scheda completa:
Pubblicato in: